Pepgen Inc. is forging ahead with tests of PGN-EDODM1 in other territories after the U.S. FDA placed a partial hold on the Freedom2-DM1 phase II trial, a multiple ascending-dose, randomized, ...

The agency acted after reviewing mouse data submitted in 2024, making the timing of the new pause “confusing,” one analyst wrote.

Shares in PepGen were down more than 21% after the FDA placed a partial clinical hold on its lead drug PGN-EDODM1, for rare ...

The timing of the partial hold is “odd,” according to analysts at Stifel, who noted that the preclinical data the FDA took ...

Shares of PepGen slid after the Food and Drug Administration put a partial clinical hold on a study of its treatment for Myotonic Dystrophy, a genetic disorder that causes progressive muscle loss and ...

PepGen (PEPG) stock dips after the FDA imposes a partial clinical hold on a mid-stage trial for its lead asset against myotonic dystrophy type 1. Read more here.

The FDA has put a partial clinical hold on PepGen’s phase 2 mus | The FDA has put a partial clinical hold on PepGen’s phase 2 muscle wasting trial after reviewing preclinical data, continuing the stop ...

Broadcom expects revenue in the current quarter ahead of expectations thanks to growing AI demand. The stock advanced 5% to $332.82 in after-hours trading Wednesday. StubHub swung to a loss and posted ...

PepGen said the Food and Drug Administration is pausing a trial evaluating its potential treatment for myotonic dystrophy. The biotechnology company said Wednesday the FDA put the Phase 2 trial on ...

PepGen said on Wednesday that the U.S. Food and Drug Administration has placed a partial clinical hold on ​its mid‑stage ...

The president and CEO of the Muscular Dystrophy Association talks about what she's most excited about in neuromuscular disease research.

While some chief executives have left for personal reasons, others have been ousted amid poor company performance.